Related Articles
VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization
Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells
Novel bone microenvironment model of castration‑resistant prostate cancer with chitosan fiber matrix and osteoblasts
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer
Antitumour activity of TH1579, a novel MTH1 inhibitor, against castration‑resistant prostate cancer